Yanni Lin

Yanni Lin has a wealth of experience in the scientific and technological development of cell therapies. Yanni began their career in 2003 as an Undergraduate Research Assistant at Tsinghua University, where they optimized protein crystalization conditions and characterized the polymerization of a protein based on chemical cross-linking and dynamic light scattering. In 2007, they earned their Master's degree from the University of Illinois at Urbana-Champaign, where they optimized an anaerobic protein expression system for mutants of E. coli Cyt bd oxidase, part of the energy chain, and cloned and expressed a novel Cyt bd Oxidase from Chlorobium ferrooxidans. In 2009, they began their PhD at the Georgia Institute of Technology, where they were responsible for optimizing activities and investigating the off-target effect of engineered nucleases. In 2014, they moved to Synthetic Genomics as a Scientist, where they generated cell lines to facilitate in vitro functional assays to assess immune responses, generated large deletions and gene knock-ins in human and pig cells using CRISPR/Cas9, and implemented methods to improve CRISPR/Cas9 multiplexing. Finally, in 2016, Yanni Lin co-founded Cure Genetics, where they served as both Co-founder and Chief Scientist and Co-founder and Chief Technology Officer, responsible for the scientific and technological development of cell therapies.

Yanni Lin obtained a B.S. in Biological Science and Biotechnology from Tsinghua University between 2003 and 2007. Following this, they obtained an M.S. in Biochemistry from the University of Illinois Urbana-Champaign between 2007 and 2009. Yanni then went on to obtain a Ph.D. in Biomedical Engineering from the Georgia Institute of Technology between 2009 and 2014. Prior to this, they attended Hainan Middle School between 2000 and 2003.